Thousands of men in England diagnosed with low- and intermediate-risk prostate cancer will soon access stereotactic ablative radiotherapy (SABR), a precision treatment that reduces the required sessions from 20 to five. NHS England reports all 48 national radiotherapy centres will offer the procedure within weeks, marking the first time this high-powered technique is available outside of clinical trials for these specific risk profiles.
How does SABR radiotherapy work?
SABR uses high-precision beams to target malignant cells while sparing surrounding healthy tissue. Prof. Peter Johnson, national clinical director for cancer at NHS England, states that this technology allows for a focused, powerful beam that limits damage to the body. Because the treatment is highly concentrated, patients require only five sessions rather than the 20 doses typical of standard radiotherapy. According to NHS officials, this reduction helps patients return to their normal routines significantly faster.
While 55,000 men are diagnosed with prostate cancer annually in England, only about 17,500 fall into the low- or intermediate-risk categories. NHS modelling estimates that approximately 3,500 men will choose the new SABR option, as many others continue to opt for active monitoring.
Why do some patients choose active monitoring instead?
Many men with low-risk prostate cancer avoid immediate intervention because the disease is often slow-growing. According to NHS data, active monitoring remains a preferred path for those whose cancer is unlikely to cause immediate harm. This clinical choice distinguishes the new SABR rollout from other cancer treatments, as it remains an elective option for those who choose to treat the disease rather than monitor it.
What is the patient experience with SABR?
Edwin Lambert, 70, a participant in current SABR trials, described the treatment as “an absolute godsend.” After an initial diagnosis in January 2025 and subsequent hormone therapy—which caused side effects like fatigue and mood swings—Lambert transitioned to the precision radiotherapy. He reported that while he experienced a temporary increase in the frequency of urination, he was able to participate in a planned archaeological dig just five weeks after his sessions concluded. He contrasted his recovery with other patients undergoing traditional, multi-week radiotherapy, who he noted appeared significantly more fatigued.
Future trends in prostate cancer care
The medical community is currently exploring the expansion of SABR to high-risk patients. Prostate Cancer UK, represented by Amy Rylance, described the current rollout as “wonderful news” that reduces the burden on patients and their families. Trials are ongoing to determine if the efficacy and safety profile of this precision technique can be extended to more aggressive forms of the disease. If these trials prove successful, the standard of care for prostate cancer could shift toward shorter, more intensive treatment regimens across all risk categories.
Frequently Asked Questions
- Is SABR available for all prostate cancer patients? No, it is currently limited to low- and intermediate-risk patients outside of trial settings.
- How many sessions are required for SABR? Patients undergo five sessions, compared to the 20 sessions required for traditional radiotherapy.
- When will this be available? NHS England expects all 48 radiotherapy centres to provide the treatment within weeks.
Have questions about your treatment options? Consult your local oncology specialist or visit the Prostate Cancer UK website for more information. Subscribe to our newsletter for the latest updates on cancer research and NHS service changes.
